Nitrate tolerance and the links with endothelial dysfunction and oxidative stress

British Journal of Clinical Pharmacology

Volumn 56, Issue 6, 2003, Pages 620-628

  Fayers, Katherine E ^a   Cummings, Michael H ^a   Shaw, Kenneth M ^a   Laight, David W ^b  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Antioxidants; Endothelial dysfunction; Nitrate tolerance; Nitric oxide; Oxidative stress; Renin angiotensin system

Indexed keywords

ANTIOXIDANT; NITRATE; NITRIC OXIDE;

CARDIOVASCULAR RISK; DRUG MECHANISM; DRUG TOLERANCE; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASODILATATION;

ARGININE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; NITRATES; NITRIC OXIDE; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; SUPEROXIDES; VASODILATION;

EID: 0345375257     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01946.x     Document Type: Review

References (79)

1. Marsh N, Marsh A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin Exp Pharmacol Physiol 2000; 27: 313-319.
2. Furchgott R, Zawadzki J. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-3766.
3. Ignarro L. Biological actions and properties of endothelium derived nitric oxide formed and released from artery and vein. Circ Res 1989; 65: 1-21.
4. Moncada S, Higgs A. The L-Arginine-Nitric Oxide pathway. NEJM 1993; 329(27): 2002-2012.
5. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature. J Pharmacol Exp Ther 1995; 274: 1067-1071.
6. Kaesemeyer W, Caldwell RB, Huang JZ, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol lowering properties. J Am Coll Cardiol 1999; 31: 234-241.
7. Abou-Mohammed G, Kaesemeyer WH, Caldwell RB, Caldwell RW. Role of 1-arginine in the vascular actions and development of tolerance to nitroglycerin. Br J Pharmacol 2000; 130: 211-218.
8. Chen Z, Zhang J, Stamler J. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA 2002; 99: 8306-8311.
9. Drexlar H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999; 31: 51-60.
10. McVeigh G. Primary nitrate tolerance in diabetes mellitus. Diabetologia 1994; 37: 115-117.
11. Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai MD. Long-term nitrate use may be deleterious in ischaemic heart disease: a study using the databases from two large-scale postinfarction studies. Am Heart J 1999; 138: 577-585.
12. Caramori PR, Adelman AG, Azevedo ER, Newton GE, Parker AB, Parker JD. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol 1998; 32: 1969-1974.
13. Gori T, Mak SS, Kelly S, Parker JD. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol 2001; 38: 1096-1101.
14. Munzel T, Heitzer T, Kurz S, et al. Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease. J Am Coll Cardiol 1996; 27: 297-303.
15. Fung H. Pharmacokinetics and pharmacodynamics of organic nitrates. Am J Cardiol 1987; 15: 4H-9H.
16. Packer M, Lee W, Kessler P, Gottlieb S, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987; 317: 799-804.
17. Munzel T, Kurz S, Heitzer T, Harrison D. New insights into mechanisms underlying nitrate tolerance. Am J Cardiol 1996; 77: 24C-30C.
18. Munzel T, Mollnau H, Hartmann M, et al. Effects of a nitrate-free interval on tolerance, vasoconstrictor sensitivity and vascular superoxide production. J Am Coll Cardiol 2000; 36: 628-634.
19. Hogstedt C, Andersson K. A cohort study on mortality among dynamite workers. J Occup Med 1979; 21: 553-556.
20. Holdright DR, Katz RJ, Wright CA, et al. Lack of rebound during intermittent transdermal treatment with glyeryl trinitrate in patients with stable angina on background beta blocker. Br Heart J 1993; 69: 223-227.
21. Munzel T, Bassenge E. Long-term angiotensin-converting enzyme inhibition with high-dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo. Circulation 1996; 93: 2052-2058.
22. Munzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci USA 1995; 92: 5244-5248.
23. Thadani U, Manyari D, Parker J, Fung H. Tolerance to the circulatory effects of oral isosorbide dinitrate. Rate of development and cross-tolerance to glyceryl trinitrate. Circulation 1980; 61: 526-535.
24. Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide dinitrate in angina pectoris, comparison of duration of action and dose-response relation during acute and sustained therapy. Am J Cardiol 1982; 49: 411-419.
25. Needleman P, Johnson EJ. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973; 184: 709-715.
26. Paker JO, Farrell B, Lahey KA, Rose BF. Nitrate tolerance, the lack of effect of N-acerylcysteine. Circulation 1987; 76: 572-576.
27. Boesgaard S, Aldershvile J, Poulsen H, Loft S, Anderson ME, Meister A. Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ Res 1994; 74: 115-120.
28. Parker J, Farrell B, Fenton T, Cohanim M, Parker J. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991; 84: 2336-2345.
29. Kim D, Rybalkin SD, Pi X, et al. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 2001; 104: 2338-2343.
30. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. J Clin Invest 1995; 95: 187-194.
31. Gryglewski R, Palmer R, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454-456.
32. Sage PR, de la Lande IS, Stafford I, et al. Nitroglycerin tolerance in human vessels: Evidence for impaired nitroglycerin bioconversion. Circulation 2000; 102: 2810-2815.
33. Milone S. Biochemical, hemodynamic, and vascular evidence concerning the free radical hypothesis of nitrate tolerance. J Cardiovasc Pharmacol 1999; 33: 685-690.
34. White C, Brock T, Chang L, et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 1044-1048.
35. Mihm M, Coyle C, Jing L, Bauer J. Vascular peroxynitrite formation during organic nitrate tolerance. J Pharmacol Exp Ther 1999; 291: 194-198.
36. Rajagopalan S, Kurz S, Munzel T, Freeman B, Griendling K, Harrison D. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH Oxidase activation. J Clin Invest 1996; 97: 1916-1923.
37. Griendling K, Minieri G, Ollerenshaw J, Alexander R. Angiotensin II stimulates NADH and NADPH oxidase axtiviry in cultures vascular smooth muscle cells. Circ Res 1994; 74(6): 1141-1148.
38. Munzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. J Clin Invest 1996; 98: 1465-1470.
39. Parker J, Parker A, Farrell B, Parker J. The effect of hydralazine on the development of tolerance to continuous nitroglycerin. J Pharmacol Exp Therapeutics 1997; 280: 866-875.
40. Pritchard K, Grooszek L, Smalley DM, et al. Low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995; 77: 510-518.
41. McDonald KK, Zharikov S, Block ER, Kilberg MS. A caveolar complex between the cationic amino acid transporter and endothelial nitric-oxide synthase may explain the 'arginine paradox'. J Biol Chem 1997; 272: 31213-31216.
42. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovascular Res 1999; 43(3): 542-548.
43. Boger RH, Bode-Boger SM, Tsao PS, Chan JR, Cooke JP. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36(7): 2287-2295.
44. MacAllister RJ, Vallance P. Nitric oxide in essential and renal hypertension. J Am Soc Nephrol 1994; 5: 1057-1056.
45. Drexlar H, Hayes D, Munzel T, Hornig B, Just H, Brunner HR. Endothelial function in chronic congestive cardiac failure. Am J Cardiol 1992; 69: 1596-1601.
46. Ohara Y, Peterson T, Zheng B, Kuo J, Harrison D. Lysophosphatidylcholine increases vascular superoxide anion production via protein kinase C activation. Arterioscler Thromb 1994; 14: 1007-1013.
47. Hirata K, Kuroda R, Sakoda T, et al. Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension 1995; 25: 180-185.
48. Sheehy A, Burson M, Black S. Nitric oxide exposure inhibits endothelial NOS activity but not gene expression. Am J Physiol 1998; 274: L833-L841.
49. Munzel T, Li H, Mollnau H, et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOSIII) gene expression, Nos III-Mediated Superoxide Production, and Vascular NO Bioavailability. Circ. Res 2000; 86: 7-12.
50. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998; 95: 9220-9225.
51. Gruhn N, Aldershvile J, Boesgaard S. Tetrahydrobiopterin improves endothelium-dependant vasodilatation in nitroglycerin-tolerant rats. Eur J Pharmacol 2001; 416: 245-249.
52. Stroes E, van Faassen E, Yo M, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000; 86: 1129-1134.
53. Gori T, Burstein J, Ahmed S, et al. Folic acid prevents nitroglycerin-induced nitric oxide synthetase dysfunction and nitrate tolerance. Circulation 2001; 104: 1119-1123.
54. Katz R, Levy WS, Buff L, Wasserman AG. Prevention of nitrate tolerance with angiotensin converting enzyme inhibitors. Circulation 1991; 83: 1271-1277.
55. Pizzulli L, Hagendorff A, Zirbes M, et al. Influence of captopril on nitroglycerin-mediated vasodilation and development of nitrate tolerance in arterial and venous circulation. Am J Cardiol 1996; 131: 342-349.
56. Cotter G, Metzkor-Cotter E, Kaluski E et al. Usefulness of Losartan, Captopril, and Furosemide in preventing nitrate tolerance and improving control of unstable angina pectoris. Am J Cardiol 1998; 82: 1024-1029.
57. Parker JD, Parker JO. Effect of therapy with an angiotensin-converting enzyme inhibitor on hemodynamic and counterregulatory responses during continuous therapy with nitroglycerin. J Am Coll Cardiol 1993; 21(6): 1445-1453.
58. Dakak N, Makhoul N, Flugelman MY et al. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990; 66: 608-613.
59. Kurz S, Hink U, Nickenig G, Borthayre A, Harrison D, Munzel T. Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation 1999; 99: 3181-3187.
60. Levine T, Levine A, Keteyian S, Narins B, Lesch M. Reverse remodelling in heart failure with intensification of vasodilator therapy. Clin Cardiol 1997; 20(8): 697-702.
61. Sung C, Aarleth A, Storer B, Ohlstein E. Angiotensin type I receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther 1994; 271(1): 429-437.
62. van den Berg R, Haenen GR, van den Berg H, Bast A. Transcription factor NF-kappaB as a potential biomarker for oxidative stress. Br J Nutr 2001; 86(Suppl 1): S121-S127.
63. Kitamoto S, Egashira K, Kataoka C, et al. Increased activity of nuclear factor-kappaB participates in cardiovascular remodelling induced by chronic inhibition of nitric oxide in rats. Circulation 2000; 102(7): 806-812.
64. Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications 2001; 15: 203-210.
65. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovascular Res 2000; 47: 457-464.
66. Kuschi L, Folsom A, Prineas R, Mink P, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996; 334: 1156-1162.
67. Blot WJ, Li JY, Taylor PR, et al. Nutritional intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 273: 1483-1492.
68. Yusuf S, Dagenais G, Pogue J, Bosch J, Davies R, Dagenais G. Vitamin E supplementation and cardiovascular events in high-risk patients: the Heart Outcomes Protection Evaluation Study investigators. N Engl J Med 2000; 342: 154-160.
69. MRC/ BHF. Heart protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 23-33.
70. Wantabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomised, double-blind, placebo controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation 1997; 96: 2545-2550.
71. Watanabe H, Kakihana M, Ohtuska S, Sugishita Y. Randomised, double blind, placebo-controlled study of the preventative effect of supplemental oral vitamin C on attenuation of nitrate tolerance. J Am Coll Cardiol 1998; 31: 1323-1329.
72. Watanabe H, Kakihana M, Ohtuska S, Sugishita Y. Randomised, double-blind, placebo-controlled study of ascorbate on the preventative effect of nitrate tolerance in patients with congestive heart failure. Circulation 1998; 97: 886-891.
73. Huie R, Padmaja S. The reaction of NO with superoxide. Free Radic Res Commun 1993; 18(4): 195-199.
74. Bassenge E, Fink N, Skatchov M, Fink B. Dietary supplement with vitamin C prevents nitrate tolerance. J Clin Invest 1998; 102: 67-71.
75. Watanabe H, Kakihana M, Ohtuska S, Sugishka Y. Randomised, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. J Am Coll Cardiol 1998; 32(5): 1194-1200.
76. Watanabe H, Kakihana M, Ohtuska S, Sugishita Y. Preventative effects of carvedilol on nitrate tolerance - a randomised, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. J Am Coll Cardiol 1998; 32(5): 1201-1206.
77. Munzel T, Keaney J. Are ACE inhibitors a 'magic bullet' against oxidative stress? Circulation 2001; 104: 1571-1574.
78. Gori T, Parker JD. Nitrate Tolerance: a unifying hypothesis. Circulation 2002; 106: 2510-2513.
79. Gori T, Parker JD. The puzzle of nitrate tolerance. Circulation 2002; 106: 2404-2408.